Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies.
Curr. Opin. Pharmacol. 53, 101-116 (2020)
Obesity and cancer cachexia are diseases at opposite ends of the BMI. However, despite the apparent dichotomy, these pathologies share some common underlying mechanisms that lead to profound metabolic perturbations. Insulin resistance, adipose tissue lipolysis, skeletal muscle atrophy and systemic inflammation are key players in both diseases. Several strategies for pharmacological treatments have been employed in obesity and cancer cachexia but demonstrated only limited effects. Therefore, there is still a need to develop novel, more effective strategies. In this review we summarize existing therapies and discuss potential novel strategies that could arise by bridging common aspects between obesity and cachexia. We discuss the potential role of macrophage manipulation and the modulation of inflammation by targeting Nuclear Receptors (NRs) as potential novel therapeutic strategies.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Necrosis-factor-alpha; Adipose-tissue Inflammation; Type-2 Diabetes-mellitus; Cell Lung-cancer; Double-blind; Skeletal-muscle; Tnf-alpha; Insulin Sensitivity; Ppar-gamma; Antibody Treatment
ISSN (print) / ISBN
1471-4892
e-ISSN
1471-4973
Journal
Current opinion in pharmacology
Quellenangaben
Volume: 53,
Pages: 101-116
Publisher
Elsevier
Publishing Place
London
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Cancer (IDC)
Grants
Deutsche Forschungsgemeinschaft DFG
Helmholtz Future Topic Aging and Metabolic Reprogramming (AMPro)
Helmholtz Future Topic Aging and Metabolic Reprogramming (AMPro)